CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05572684
Title field or adapter rule: {'original_value': 'A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-30T23:06:05.473663+00:00
Published At: 2026-08-13T00:00:00+00:00
Record Updated At: 2026-08-13
Results Posted At: 2026-08-13
Source Retrieved At: 2026-10-30T22:07:43.943614+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Advanced or Metastatic Solid Tumors", "Microsatellite Instability Low", "Microsatellite Instability High", "Microsatellite Stable", "Ovarian Cancer", "Gastric Cancer", "Colo-rectal Cancer", "Esophageal Cancer", "Endometrial Cancer", "Head Neck Cancer", "Cervical Cancer", "Lung Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-08-13", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT05572684"
protocolSection.identificationModule.officialTitle: "A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Na\u00efve MSS/MSI-Low Solid Tumors"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: {"date": "2026-08-13", "type": "ACTUAL"}

{'armGroupLabels': ['NC410 and pembrolizumab'], 'description': 'NC410 will be given intravenously (IV) every 2 weeks', 'name': 'NC410', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['NC410 and pembrolizumab'], 'description': 'Pembrolizumab 400mg will be given IV every 6 weeks.', 'name': 'pembrolizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.